Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 999-1015

  Mudra, Daniel R ^a,b   Jin, Jin Y ^b   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Clearance; In silico modeling; Intestinal absorption; Intestinal metabolism; Mathematical model; Membrane transport; P glycoprotein; Paracellular transport; Pharmacokinetics

Indexed keywords

ATENOLOL; CYTOCHROME P450 3A; EDETIC ACID; ELACRIDAR; GLYCOPROTEIN P; KETOCONAZOLE; NORVERAPAMIL; VALSPODAR; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; INTESTINE MUCOSA; MICHAELIS MENTEN KINETICS; NONHUMAN; PERFUSION; PHYSIOLOGY; QUANTITATIVE ANALYSIS; RAT;

EID: 74049108875     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21965     Document Type: Article

References (36)

1. Borchardt RT, Kearns EH, Lipinski CA, Thakker DR, Wang B, editors. 2004. Biotechnology: Pharmaceutical aspects. Volume I: Pharmaceutical profiling in drug discovery for lead selection. Arlington, VA: AAPS Press.
2. Borchardt RT, Smith PL, Wilson G, editors. 1996. Pharmaceutical biotechnology: Models for assessing drug absorption and metabolism. New York, NY: Plenum Press.
3. Ribadeneira MD, Aungst BJ, Eyermann CJ, Huang SM. 1996. Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Pharm Res 13:227-233.
4. Sababi M, Borgå O, Hultkvist-Bengtsson U. 2001. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 14:21-27.
5. Iwao T, Inoue K, Hayashi Y, Yuasa H, Watanabe J. 2002. Metabolic extraction of nifedipine during absorption from the rat small intestine. Drug Metab Pharmacokinet 17:546-553.
6. Johnson BM, Chen W, Borchardt RT, Charman WN, Porter CJH. 2003. A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther 305:151-158.
7. Iwao T, Inoue K, Hayashi Y, Yuasa H, Watanabe J. 2004. Absorption and metabolic extraction of diltiazem from the perfused rat small intestine. Drug Metab Pharmacokinet 19:430-437.
8. Varma MV, Panchagnula R. 2005. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: Kinetic analysis of quinidine efflux in situ. J Pharm Sci 94: 2632-2643.
9. Lane ME, Corrigan OI. 2006. Paracellular and transcellular pathways facilitate insulin permeability in rat gut. J Pharm Pharmacol 58:271-275.
10. Kavin H, Levin NW, Stanley MM. 1967. Isolated perfused rat small bowel - Technic, studies of viability, glucose absorption. J Appl Physiol 22:604-611.
11. Ho NFH, Park JY, Ni PF, Huguchi WI. 1983. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animal and man. In: Crouthamel WG, Sarapu A, editors. Animal models for oral drug deliver in man: In situ and in vivo approaches. Washington, DC: AphA/APS. pp 27-106.
12. Griffiths R, Lewis A, Jeffrey P. 1996. Models of drug absorption in situ and in conscious animals. In: Borchardt RT, Smith P, Wilson G, editors. Models for assessing drug absorption and metabolism. New York, New York: Plenum Press. pp 67-82.
13. Bourdet DL, Pollack GM, Thakker DR. 2006. Intestinal absorptive transport of the hydrophilic cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res 23:1178-1187.
14. Munoz MJ, Merino-Sanjuan M, Lledo-Garcia R, Casabo VG, Manez-Castillejo FJ, Nacher A. 2005. Use of nonlinear mixed effect modeling for the intestinal absorption data: Application to ritonavir in the rat. Eur J Pharm Biopharm 61:20-26.
15. Valenzuela B, Lopez-Pintor E, Perez-Ruxio JJ, Nacher A, Martin-Villodre Am Casabo VG. 2006. Modelling intestinal absorption of salbutamol sulphate in rats. Int J Pharm 314:21-30.
16. Gonzalez-Alvarez I, Fernandez-Teruel C, Casabo-Alos VG, Garrigues TM, Polli JE, Garcia-Ruiz A, Bermejo M. 2007. In situ kinetic modeling of intestinal efflux in rats: Functional characterization of segmental differences and correlation with in vitro results. Biopharm Drug Dispos 28:229-239.
17. McAllister RG, Tan TG. 1980. Effect of hypothermia and drug metabolism. Pharmacology 20:95-100.
18. Nelson WL, Olsen LD, Beitner DB, Pallow RJ. 1988. Regioselectivity and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver. Drug Metab Dispos 16:184-188.
19. 3H]-verapamil radioligand-binding assay. J Pharmacol Exp Ther 288:348-357.
20. Sandstrom R, Lennernas H. 1999. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab Dispos 27:951-955.
21. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. 1999. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65:283-290.
22. Neuhoff S, Langguth P, Dressler C, Anderson TB, Regardh CG, Spahn-Langguth H. 2000. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 38:168-179.
23. Lee YH, Perry B, Lee HS, Kunta JR, Sutyak JP, Sinko PJ. 2001. Differentiation of gut and hepatic first-pass effect of drugs. 1. Studies of verapamil in ported dogs. Pharm Res 18:1721-1728.
24. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quantitative evaluation of the function of small intestinal P-glycoprotein: Comparative studies between in situ and in vivo. Pharm Res 20:1163-1169.
25. Johnson BM, Charman WN, Porter CJH. 2003. Application of compartmental modeling to an examination of intestinal permeability data: Assessing the impact of tissue uptake, P-glycoprotein and CYP3A. Drug Metab Dispos 31:1151-1160.
26. Mudra DM, Borchardt RT. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. J Pharm Sci (submitted).
27. Iglewicz B, Hoaglin DC. 1993. How to detect and handle outliers, Vol. 16. Milwaukee, WI: ASQC Quality Press.
28. Artursson P, Magnusson C. 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 79:595-600.
29. Gan LS, Hsyu PH, Pritchard JF, Thakker D. 1993. Mechanism of intestinal absorption of ranitidine and ondansetron: Transport across Caco-2 cell monolayers. Pharm Res 10:1722-1725.
30. Knipp GT, Ho NF, Barsuhn CL, Borchardt RT. 1997. Paracellular diffusion in Caco-2 cell monolayers: Effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 86:1332-1340.
31. Stein WD. 1997. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Phys Rev 77:545-590.
32. Wang EL, Lew K, Casciano CN, Lement RP, Johnson WW. 2002. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 46:160-165.
33. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. 2003. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20:757-764.
34. Achira M, Suzuki H, Ito K, Sugiyama Y. 1999. Comparative studies to determine selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm Sci 1:E18.
35. Hyafil F, Vergely C, DuVignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF-120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
36. Houston JB, Kenworthy KE, Galetin A. 2003. Typical and atypical enzyme kinetics. In: Lee JS, Obach RS, Fisher MB, editors. Drug metabolizing enzymes: Cytochrome P450 and other enzymes in drug discovery and development. Boca Raton, FL: CRC Press. pp 211-254.